Shares of Dendreon traded up 7.78% during mid-day trading on Monday, hitting $6.37. Dendreon has a 52 week low of $5.69 and a 52 week high of $42.00. The company’s market cap is $941.1 million.
DNDN has been the subject of a number of other recent research reports. Analysts at Robert W. Baird reiterated a “neutral (n/a)” rating on shares of Dendreon in a research note to investors on Monday. Separately, analysts at Wedbush reiterated an “underperform” rating on shares of Dendreon in a research note to investors on Monday. They now have a $4.00 price target on the stock, down previously from $5.00. Finally, analysts at Jefferies Group (NYSE: JEF) reiterated an “underperform (n/a)” rating on shares of Dendreon in a research note to investors on Monday.
Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may improve cancer treatment options for patients.